[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Ivermectin trial, Oxford University", "description": "Ivermectin Arm of PRINCIPLE Trial Put on Hold?\n\nhttps://www.medpagetoday.com/special-reports/exclusives/96194\n\nMedPage Today, Merck\n\"concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and have prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19.\"\n\"If clinical data emerge providing definitive evidence for a positive benefit-risk assessment of the use of ivermectin in COVID-19, we stand ready to provide our expertise and resources as needed,\"\n\nIvermectin, PRINCIPLE trial\n\nhttps://www.principletrial.org\n\nhttps://www.principletrial.org/news/ivermectin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-oxford2019s-principle-trial\n\nhttps://www.principletrial.org/news\n\nProfessor Chris Butler, from the University Oxford\u2019s Nuffield Department of Primary Care Health Sciences, \n\nJoint Chief Investigator of the PRINCIPLE trial, said, \n\n\u2018Ivermectin is readily available globally, \n\nhas been in wide use for many other infectious conditions so it\u2019s a well-known medicine with a good safety profile, \n\nand because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries.\n\nInternational Standard Randomised Controlled Trial Number\n\nhttps://www.isrctn.com/ISRCTN86534580?q=ivermectin&filters=&sort=&offset=4&totalResults=25&page=1&pageSize=10&searchType=basic-search\n\nWhen is the study starting and how long is it expected to run for?\n\nMarch 2020 to September 2022\n\nFavipiravir\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713175/\n\nhttps://bnf.nice.org.uk/treatment-summary/influenza.html\n\nIvermectin\n\nhttps://bnf.nice.org.uk/drug/ivermectin.html\n\nA double blind trial\n\nIndependent Data Monitoring and Safety Committee\n\nWill pick up a signal for futility, superiority, or safety\n\nWill let the Trial Steering Committee know\n\nThen a final analysis can be conducted, followed by the release of results and data", "link": "https://www.youtube.com/watch?v=c9bgCG5WgTQ", "date_published": "2022-02-09 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Omicron spreading between animals", "description": "Reverse zoonosis to deer\n\nCDC\n\nCases and deaths\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailycases\n\nNew hospital admissions\n\nhttps://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions\n\nCurrent hospital patients\n\nhttps://covid.cdc.gov/covid-data-tracker/#hospitalizations\n\nUK official data\n\nhttps://coronavirus.data.gov.uk\n\nUK Zoe data\n\nhttps://covid.joinzoe.com/data#levels-over-time\n\nNovavax COVID-19 vaccine Nuvaxovid approved by MHRA\n\nhttps://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra\n\nThe approval authorises the use of this vaccine in people aged 18 and over for a first and second dose.\n\nProtein based platform (like hep B, shingles)\n\nCan be stored in refrigerator\n\nEfficacy\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2116185\n\nOriginal variant, 96%\n\nAlpha variant, 86%\n\nBeta, 60%\n\nUS and Mexico (n = 30,000), 90.4%\n\nDeveloping an Omicron-specific version\n\nThird dose now under testing\n\nMix and match should be good\n\nUS, School mask mandates\n\nhttps://www.nytimes.com/live/2022/02/08/world/covid-test-vaccine-cases\n\nGov. Philip D. Murphy, New Jersey\n\nSecond week of March, students and school employees, no longer be required to wear masks.\n\nThis is not a declaration of victory as much as an acknowledgment that we can responsibly live with this thing\nReverse zoonosis to deer\n\nhttps://www.nytimes.com/2022/02/07/health/omicron-deer-staten-island-covid.html\n\nhttps://www.biorxiv.org/content/10.1101/2022.02.04.479189v1\n\nFull PDF \n\nhttps://www.biorxiv.org/content/10.1101/2022.02.04.479189v1.full.pdf\n\nWhite-tailed deer (Odocoileus virginianus)\n\nHighly susceptible to infection by SARS-CoV-2\n\nMultiple reports of widespread spillover from humans to free-living deer\n\nSARS-CoV-2 B.1.1.529 Omicron variant\n\nStaten Island, New York, December 12th 2021 to January 31st 2022\n\nWhite-tailed deer opportunistically sampled on Staten\n\n19 of the 131 (14.5%) were positive for SARS-CoV-2\n\nP.C.R. testing, n = 68 deer\n\nSeven actively infected at the time of sampling\n\nSpecific serum antibodies indicating prior exposure \n(? Omicron or previous)\n\nWhole-genome sequencing identified Omicron (n = 4)\n\nCirculating amongst the white-tailed deer on Staten Island\n\nPhylogenetic Omicron sequences clustered closely with sequences recovered from infected humans in New York\n\nHuman to deer spillover\n\nUrgent need for comprehensive surveillance of susceptible animal species,\n\nto identify ecological transmission networks\n \nand better assess the potential risks of spillback to humans\n\nVirus may be evolving to adapt to the new host\n\nInfected with earlier variants\n\nArkansas, Illinois, Kansas, Maine, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Oklahoma, Pennsylvania, Tennessee and Virginia\n\n(Deer have appeared asymptomatic when infected with earlier variants)", "link": "https://www.youtube.com/watch?v=v3Kg7TjmpLA", "date_published": "2022-02-08 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]